Clinical Trial Update: Safety Study of Roflumilast Cream 0.05% in Infants Aged 3 Months to Less Than 2 Years With Atopic Dermatitis [Phase 2]

View source ↗

Summary

Arcutis Biotherapeutics completed a Phase 2 safety trial evaluating Roflumilast Cream 0.05% in infants aged 3 months to under 2 years with atopic dermatitis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• Roflumilast Cream 0.05% (roflumilast)

Snippet

Sponsor: Arcutis Biotherapeutics, Inc. | Conditions: Atopic Dermatitis (Eczema) | Phase 2 | Status: COMPLETED